Abstract
Glycolytic activity and hypoxia are associated with poor prognosis and radiation resistance. Including both the tumor uptake of 2-deoxy-2-[18 F]-fluorodeoxyglucose (FDG) and the proposed hypoxia tracer copper(II)diacetyl-bis(N4)-methylsemithio-carbazone (Cu-ATSM) in targeted therapy planning may therefore lead to improved tumor control. In this study we analyzed the overlap between sub-volumes of FDG and hypoxia assessed by the uptake of 64Cu-ATSM in canine solid tumors, and evaluated the possibilities for dose redistribution within the gross tumor volume (GTV).
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Radiation Oncology |
| Vol/bind | 8 |
| Sider (fra-til) | 262 |
| ISSN | 1748-717X |
| DOI | |
| Status | Udgivet - 2013 |
Fingeraftryk
Dyk ned i forskningsemnerne om 'Dose escalation to high-risk sub-volumes based on non-invasive imaging of hypoxia and glycolytic activity in canine solid tumors: a feasibility study'. Sammen danner de et unikt fingeraftryk.Citationsformater
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS